BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008;14:788-796. [PMID: 18245540 DOI: 10.1158/1078-0432.ccr-07-0524] [Cited by in Crossref: 59] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Gnanasambandan K, Magis A, Sayeski PP. The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617. Biochemistry 2010;49:9972-84. [PMID: 20958061 DOI: 10.1021/bi1014858] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
2 Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, Hédou D, Viaud-Massuard MC, Prié G, Gouilleux F. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Cancers (Basel) 2020;12:E240. [PMID: 31963765 DOI: 10.3390/cancers12010240] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
3 Zhang SP, Wang Z, Wang LX, Liu SJ. AG490: An inhibitor of hepcidin expression in vivoWorld J Gastroenterol 2011; 17(45): 5032-5034 [PMID: 22174555 DOI: 10.3748/wjg.v17.i45.5032] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
4 Li D, Lu N, Han J, Chen X, Hao W, Xu W, Liu X, Ye L, Zheng Q. Eriodictyol Attenuates Myocardial Ischemia-Reperfusion Injury through the Activation of JAK2. Front Pharmacol 2018;9:33. [PMID: 29441020 DOI: 10.3389/fphar.2018.00033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
5 Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W, Giraud AS. Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One. 2014;9:e95993. [PMID: 24804649 DOI: 10.1371/journal.pone.0095993] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
6 Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, Sawaya R, Aldape K, Cavenee WK, Bogler O, Furnari FB. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. Int J Cancer 2013;132:509-20. [PMID: 22729867 DOI: 10.1002/ijc.27690] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
7 Gaun V, Patchen B, Volovetz J, Zhen AW, Andreev A, Pollastri MP, Fraenkel PG. A chemical screen identifies small molecules that regulate hepcidin expression. Blood Cells Mol Dis 2014;53:231-40. [PMID: 24998898 DOI: 10.1016/j.bcmd.2014.06.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
8 Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther 2010;9:2026-36. [PMID: 20606045 DOI: 10.1158/1535-7163.MCT-10-0238] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
9 Seo IA, Lee HK, Shin YK, Lee SH, Seo SY, Park JW, Park HT. Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130. Korean J Physiol Pharmacol. 2009;13:131-138. [PMID: 19885008 DOI: 10.4196/kjpp.2009.13.2.131] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
10 Yu J, Yuan X, Liu Y, Zhang K, Wang J, Zhang H, Liu F. Delayed Administration of WP1066, an STAT3 Inhibitor, Ameliorates Radiation-Induced Lung Injury in Mice. Lung 2016;194:67-74. [PMID: 26563331 DOI: 10.1007/s00408-015-9821-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
11 Chan D, Koren-Michowitz M. Update on JAK2 Inhibitors in Myeloproliferative Neoplasm. Ther Adv Hematol 2011;2:61-71. [PMID: 23556077 DOI: 10.1177/2040620711401646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Nagao T, Oshikawa G, Wu N, Kurosu T, Miura O. DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3β. PLoS One 2011;6:e27397. [PMID: 22087308 DOI: 10.1371/journal.pone.0027397] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
13 Tasian SK, Loh ML. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia. Crit Rev Oncog 2011;16:13-24. [PMID: 22150304 DOI: 10.1615/critrevoncog.v16.i1-2.30] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
14 Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, Wang VM, Senturk S, Fellmann C, Ding D, Beinortas T, Kleinman D, Chen M, Sordella R, Wilkinson JE, Castillo-Martin M, Cordon-Cardo C, Robinson BD, Trotman LC. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discov 2015;5:636-51. [PMID: 25829425 DOI: 10.1158/2159-8290.CD-14-1113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
15 Barosi G, Rosti V. Novel strategies for patients with chronic myeloproliferative disorders. Curr Opin Hematol 2009;16:129-34. [PMID: 19468275 DOI: 10.1097/MOH.0b013e3283257a9e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT. Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development? Cancers (Basel) 2021;13:5204. [PMID: 34680353 DOI: 10.3390/cancers13205204] [Reference Citation Analysis]
17 Hixson KM, Cogswell M, Brooks-Kayal AR, Russek SJ. Evidence for a non-canonical JAK/STAT signaling pathway in the synthesis of the brain's major ion channels and neurotransmitter receptors. BMC Genomics 2019;20:677. [PMID: 31455240 DOI: 10.1186/s12864-019-6033-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
18 Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 2011;71:3831-40. [PMID: 21512135 DOI: 10.1158/0008-5472.CAN-10-4002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
19 Sayyah J, Sayeski PP. Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. Curr Oncol Rep 2009;11:117-24. [PMID: 19216843 DOI: 10.1007/s11912-009-0018-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
20 Quintás-Cardama A, Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, Kantarjian HM, Verstovsek S. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs 2011;29:818-26. [PMID: 20372971 DOI: 10.1007/s10637-010-9429-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
21 Yeung YT, McDonald KL, Grewal T, Munoz L. Interleukins in glioblastoma pathophysiology: implications for therapy. Br J Pharmacol 2013;168:591-606. [PMID: 23062197 DOI: 10.1111/bph.12008] [Cited by in Crossref: 111] [Cited by in F6Publishing: 104] [Article Influence: 12.3] [Reference Citation Analysis]
22 Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, Hayakawa M, Sumitomo M, Asano T. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010;102:1592-9. [PMID: 20461084 DOI: 10.1038/sj.bjc.6605691] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 6.8] [Reference Citation Analysis]
23 Laubach JP, Fu P, Jiang X, Salter KH, Potti A, Arcasoy MO. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp Hematol 2009;37:1411-22. [PMID: 19815050 DOI: 10.1016/j.exphem.2009.09.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
24 Qin JJ, Yan L, Zhang J, Zhang WD. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res 2019;38:195. [PMID: 31088482 DOI: 10.1186/s13046-019-1206-z] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 32.7] [Reference Citation Analysis]
25 Malińska M, Fokt I, Priebe W, Woźniak K. Bromine Atom Interactions in Biologically Active Acrylamide Derivatives. Crystal Growth & Design 2015;15:2632-42. [DOI: 10.1021/cg501598h] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
26 Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett 2009;19:3598-601. [PMID: 19447617 DOI: 10.1016/j.bmcl.2009.04.138] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
27 Tolomeo M, Cascio A. The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy. Int J Mol Sci 2021;22:E603. [PMID: 33435349 DOI: 10.3390/ijms22020603] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Schuber PT Jr, Pal A, Ying Y, Han D, Gao L, Wang S, Levitzki A, Kapuria V, Talpaz M, Young M, Showalter HD, Donato NJ, Bornmann WG. Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). Bioorg Med Chem 2014;22:1450-8. [PMID: 24457091 DOI: 10.1016/j.bmc.2013.12.048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]